Primary End-Points for Prophylactic HPV Vaccine Trials
This report presents the findings of an expert group that examined under what circumstances human papillomavirus (HPV) vaccine efficacy can be established at an earlier stage of infection, rather than the clinical onset of disease. It also shows how the evaluation and licensing of prophylactic HPV vaccines could be significantly accelerated.
Author: International Agency for Research on Cancer
» Download file (English)
934 KB PDF (Located at www.iarc.fr)
Resource types: Report
Diseases/vaccines: Human papillomavirus (HPV)